Table IV.
Univariate and multivariate analysis using Cox's proportional hazard regression model for disease-free survival.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Clinicopathological parameters | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age (<60 vs. ≥60 years) | 1.332 (0.861-2.060) | 0.198 | ||
| Sex (male vs. female) | 1.178 (0.782-1.775) | 0.433 | ||
| DM (yes vs. no) | 0.794 (0.457-1.381) | 0.415 | ||
| Tumor location (right vs. left) | 0.976 (0.634-1.504) | 0.914 | ||
| Vascular invasion (yes vs. no) | 2.020 (1.241-3.288) | 0.005 | 1.629 (0.951-2.791) | 0.076 |
| Lymphatic invasion (yes vs. no) | 2.075 (1.364-3.156) | 0.001 | 0.643 (0.386-1.071) | 0.090 |
| Perineural invasion (yes vs. no) | 2.723 (1.807-4.105) | <0.001 | 1.812 (1.153-2.847) | 0.010 |
| AJCC stage (I, II vs. III, IV) | 4.588 (2.923-7.200) | <0.001 | 4.515 (2.706-7.532) | <0.001 |
| TET2 (high vs. low) | 0.582 (0.348-0.975) | 0.040 | 0.568 (0.339-0.952) | 0.032 |
| AMPK (high vs. low) | 1.586 (1.029-2.444) | 0.037 | 1.359 (0.865-2.137) | 0.183 |
| AMPK high/TET2 low vs. AMPK low/TET2 high | 3.569 (1.579-8.066) | 0.002 | 2.840 (1.241-6.498) | 0.013 |
HR, hazard ratio; AMPK, AMP-activated protein kinase; TET2, ten eleven translocation 2; DM, diabetes mellitus; AJCC, American Joint Committee on Cancer.